0001179110-14-011698.txt : 20140711
0001179110-14-011698.hdr.sgml : 20140711
20140711173226
ACCESSION NUMBER: 0001179110-14-011698
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140709
FILED AS OF DATE: 20140711
DATE AS OF CHANGE: 20140711
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACCELERON PHARMA INC
CENTRAL INDEX KEY: 0001280600
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SYDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-9200
MAIL ADDRESS:
STREET 1: 128 SYDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sherman Matthew L
CENTRAL INDEX KEY: 0001325710
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36065
FILM NUMBER: 14972447
MAIL ADDRESS:
STREET 1: C/O ACCELERON PHARMA INC
STREET 2: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2014-07-09
0
0001280600
ACCELERON PHARMA INC
XLRN
0001325710
Sherman Matthew L
128 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
SVP & Chief Medical Officer
Common Stock
2014-07-09
4
M
0
6000
0.48
A
19858
D
Common Stock
2014-07-09
4
S
0
2906
28.55
D
16952
D
Common Stock
2014-07-09
4
S
0
3094
29.39
D
13858
D
Common Stock
2014-07-09
4
S
0
1001
28.77
D
31499
I
By GRAT
Common Stock
2014-07-09
4
S
0
499
29.46
D
31000
I
By GRAT
Option to Purchase Common Stock
0.48
2014-07-09
4
M
0
6000
0
D
2016-05-31
Common Stock
47765
41765
D
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2014.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.16 to $29.15, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.17 to $29.66, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.28 to $29.18, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.33 to $29.58, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
The options of registrant's common stock vested as to 25% of the shares on the first anniversary of the grant and in equal installments quarterly thereafter.
/s/ John Quisel, as attorney-in-fact for Matthew L. Sherman
2014-07-11